The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 07, 2025
Filed:
Nov. 09, 2021
Ossianix, Inc, Philadelphia, PA (US);
Pawel Stocki, Hertfordshire, GB;
Jaroslaw Michal Szary, Cambridge, GB;
Krzysztof Bartlomiej Wicher, Cambridge, GB;
Laura Thei, Cambridge, GB;
Julia Lynn Rutkowski, Bryn Mawr, PA (US);
Mykhaylo Demydchuk, Cambridge, GB;
Shu-Fen Coker, Amersham, GB;
Ossianix, Inc., Philadelphia, PA (US);
Abstract
The present invention relates to a high affinity, VNAR polypeptide cross reactive with primate transferrin receptors ('TfR'). This TfR-specific VNAR polypeptide was obtained by screening semisynthetic VNAR phage display libraries against recombinant human TfR-1. The VNAR polypeptides of the invention can be used alone or as a component in conjugates that target the transferrin/transferrin receptor transport system. The invention further includes use of this VNAR, its conjugates and other derivatives in diagnostic and therapeutic methods, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier or other membrane systems. This TfR-specific VNAR polypeptide can also be used to target other biological barriers such the intestines, the placenta or aberrant cells overexpressing TfR-1, for therapeutic benefit in treatment of certain cancer cells and tumors of various tissue types. Deimmunized VNAR scaffolds are also provided.